RenovoRx, Inc. (RNXT)
| Market Cap | 57.20M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.90M |
| Shares Out | 7.63M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,016 |
| Open | 7.35 |
| Previous Close | 7.35 |
| Day's Range | 7.02 - 7.70 |
| 52-Week Range | 6.66 - 16.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About RNXT
RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for our lead product candidate RenovoGem. Our therapy platform, RenovoTAMP, combines our patented FDA cleared delivery system, RenovoCath®, with small molecule chemotherapeutic agents that can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. While we anticipate investigating other chemotherapeutic agents for int...
Financial Performance
Financial StatementsNews
RNXT Stock: The FDA News That Has Biotech Company RenovoRx Rocketing Higher Today
RenovoRx (RNXT) stock is running higher on Tuesday following news that the U.S. Food and Drug Administration granted it new 501(k) clearance. The post RNXT Stock: The FDA News That Has Biotech Company R...
See Why RenovoRx Stock Is Shooting Higher On Tuesday
The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ:RNXT) RenovoCath Delivery System. The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.
RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid T...
LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- RenovoRx , Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clear...
RenovoRx Announces Pricing of Initial Public Offering
RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, today announced the pricing of its underwritten initial...
RenovoRx IPO Registration Document (S-1)
RenovoRx, Inc. has filed to go public with an IPO on the NASDAQ.